Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Corcept Therapeutics (CORT) Revenue (2016 - 2025)

Corcept Therapeutics' Revenue history spans 10 years, with the latest figure at $202.1 million for Q4 2025.

  • For Q4 2025, Revenue rose 11.12% year-over-year to $202.1 million; the TTM value through Dec 2025 reached $761.4 million, up 12.79%, while the annual FY2025 figure was $761.4 million, 12.79% up from the prior year.
  • Revenue for Q4 2025 was $202.1 million at Corcept Therapeutics, down from $207.6 million in the prior quarter.
  • Across five years, Revenue topped out at $207.6 million in Q3 2025 and bottomed at $79.4 million in Q1 2021.
  • The 5-year median for Revenue is $120.7 million (2023), against an average of $134.3 million.
  • The largest annual shift saw Revenue dropped 14.81% in 2021 before it surged 47.69% in 2024.
  • A 5-year view of Revenue shows it stood at $98.8 million in 2021, then grew by 4.28% to $103.1 million in 2022, then soared by 31.39% to $135.4 million in 2023, then surged by 34.33% to $181.9 million in 2024, then increased by 11.12% to $202.1 million in 2025.
  • Per Business Quant, the three most recent readings for CORT's Revenue are $202.1 million (Q4 2025), $207.6 million (Q3 2025), and $194.4 million (Q2 2025).